New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

Ling-Shan Syue; Yen-Hsu Chen; Wen-Chien Ko; Po-Ren Hsueh

doi:10.1016/j.ijantimicag.2015.12.021

New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

Int J Antimicrob Agents. 2016 Apr;47(4):250-8. doi: 10.1016/j.ijantimicag.2015.12.021. Epub 2016 Feb 21.

Authors

Ling-Shan Syue¹, Yen-Hsu Chen², Wen-Chien Ko³, Po-Ren Hsueh⁴

Affiliations

¹ Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
² Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan.
³ Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: winston3415@gmail.com.
⁴ Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University, College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.

PMID: 27005457
DOI: 10.1016/j.ijantimicag.2015.12.021

Abstract

The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

Keywords: Antimicrobial resistance; Avibactam; Ceftolozane; Eravacycline; Intra-abdominal infections; Plazomicin.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / isolation & purification
Anti-Bacterial Agents / therapeutic use*
Bacterial Infections / drug therapy*
Bacterial Infections / microbiology*
Drug Resistance, Microbial*
Humans
Intraabdominal Infections / drug therapy*
Intraabdominal Infections / microbiology*

Substances

Anti-Bacterial Agents